GDC-0032 (Taselisib)
Important Notice: For research use only. We do not sell to patients.
Loading distributor info...
Important Notice: For research use only. We do not sell to patients.
Loading distributor info...
Discription | GDC-0032 is a potent, next-generation PI3 inhibitor targeting PI3 alpha. | ||
---|---|---|---|
Targets |
|
Catalog Num | A12831 |
---|---|
Formula | C24H28N8O2 |
Molecular Weight | 460.53 |
CAS Number | 1282512-48-4 |
SMILES | CC1=NN(C(=N1)C2=CN3CCOC4=C(C3=N2)C=CC(=C4)C5=CN(N=C5)C(C)(C)C(=O)N)C(C)C |
Synonyms | GDC 0032, GDC0032 |
Storage | Store lyophilized at -20ºC, keep desiccated. |
In vitro | DMSO | Warmed: 62 mg/mL (134.62 mM) | |
Water | Insoluble | ||
Ethanol | Insoluble | ||
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
0.1 mM | 21.71 mL | 108.57 mL | 217.14 mL |
0.5 mM | 4.34 mL | 21.71 mL | 43.43 mL |
1 mM | 2.17 mL | 10.86 mL | 21.71 mL |
5 mM | 0.43 mL | 2.17 mL | 4.34 mL |
Calculate the dilution required to prepare a stock solution. This equation is commonly abbreviated as: C1V1 = C2V2